



Medi-Cal Rx

Coming Soon: Commercial JYNNEOS®

Vaccine Reimbursement Correction

October 4, 2024

Background

On April 1, 2024, Bavarian Nordic commercially launched the JYNNEOS® vaccine, identified by the 11-digit NDCs 50632000101 and 50632000103. Claims submitted with these NDCs with a date of service (DOS) on or after April 1, 2024, are a covered Medi-Cal Rx benefit. These NDCs qualify for reimbursement for the ingredient cost, dispensing fee, and administration fee.

What Pharmacy Providers Need to Know

Medi-Cal Rx identified that reimbursement for commercial vaccines has been incorrect for claims submitted with a DOS on or after April 1, 2024, with NDC 50632000101, and for claims submitted with a DOS on or after September 13, 2024, with NDC 50632000103.

Medi-Cal Rx will implement a resolution and reprocess all eligible claims through the mass adjustment process at a later date. Medi-Cal Rx will publish an alert and notification with details on the [Bulletin & News](#) and the [Mass Adjustments](#) pages on the [Medi-Cal Rx Provider Portal](#).

What Pharmacy Providers Need to Do

No additional action is required by pharmacy providers at this time.

Resources

- [Vaccines For Children Program: Medi-Cal Reference Guide](#)
- [Vaccines For Children Program Policy and Billing Guidance for Pharmacy Providers](#)
- [Medi-Cal Reimbursement of Vaccines For Children \(VFC\)-Enrolled Pharmacy Providers and for VFC and Non-VFC Vaccines – Frequently Asked Questions \(FAQs\)](#)
- [JYNNEOS Vaccine Commercial Transition](#)
- [Bulletin & News](#) and the [Mass Adjustments](#) pages on the Medi-Cal Rx Provider Portal

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.